Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$36.69
▼ $0.05 (-0.1%)
Market data updated: 09/26 11:02 PM
Fundamentals updated: 09/26/2026
News analyzed: 09/26/2026
Market Cap
$3.54B
Day Range
$36.34 - $36.98
52-Week Range
$26.05 - $42.68
Beta
—
Next Earnings
02.11.2026
Support
$34.01
Resistance
$42.68
IDYA is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+42.8% (1Y)
Strengths: 11/29 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🟡 Mixed
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Revenue growth (last year)
Revenue growth (last year): 3024.4%
Growth
Biggest negative driver
DCF Fair Value
Estimated fair value: -$21.18 vs. price $36.69 (-157.7%)
Fair Value
Signal tension
Growth scores strong (82/100), but fair-value analysis scores this stock as relatively expensive (38/100) — the growth story and the current price aren't fully aligned.
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 3 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 3
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
47
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
82
Quality
63
Value
38
Momentum
26
Risk
54
Sentiment
68
Fundamental
34
Institutional
50
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of IDEAYA Biosciences has focused on its progress in oncology drug development, particularly for lung and pancreatic cancers. The company announced a successful FDA meeting for its Phase 3 trial of IDE849 in extensive-stage small cell lung cancer, plans a Phase 3 study by year-end 2026, and upcoming investor events to share research updates. Analysts reiterated an "Outperform" rating, while darovasertib’s advancing clinical data and funding milestones were also highlighted.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about IDEAYA Biosciences, Inc.. News trend score: 68. Reason: 5 of the last 20 articles are positive, versus 2 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
15
🎯 Conviction (vs. Emotion)
74
Psychology
17
Fundamentals
34
Technical
26
Valuation
38
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
-0%
Market Narrative
46
Fundamental Reality
74
Narrative Gap
-28
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
IDYA’s psychology profile is fragmented but leans toward speculative excitement, with euphoria (26) and herding (29) as dominant forces. The narrative-reality gap (-17) suggests traders may be overestimating momentum relative to fundamentals, while positive sentiment and outperformance vs. peers fuel herd-like behavior. Overconfidence is muted but present, as price momentum exceeds earnings growth. The key question: Is this momentum sustainable, or will traders pivot if peers underperform further? No single bias dominates, but the blend of euphoria and herding creates a fragile equilibrium.
Updated: 09/06/2026, 05:42 PM
What could change this?
👥 What the crowd believes
"IDEAYA Biosciences announced a successful FDA Type C meeting to determine the Phase 3 registrational trial design for IDE849 in extensive stage small cell lung cancer (article 6)."
"IDEAYA Biosciences announces London Investor R&D Day and participation in upcoming September 2026 investor conferences (article 1)."
"IDEAYA Biosciences partners with Genentech for a clinical trial in MTAP-deleted KRAS G12D-mutant pancreatic cancer (article 12)."
"Citizens reiterates Market Outperform on IDEAYA Biosciences, maintains $42 price target (article 2)."
📈 3D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 100/100
🔴 Weakest match
Thorstein Veblen — 30/100
🗣️ Why do they disagree?
Based on the documented principles of each investor, the model estimates that the high scores from Bagehot, Lynch, Nelson and Fisher reflect a consensus that IDYA enjoys strong liquidity, attractive growth relative to price, a favorable cycle position, and solid company quality. In contrast, Graham’s mixed verdicts and the lower scores from the efficient‑market view, Marks and the enterprising Graham framework indicate concerns about valuation, possible over‑optimism and limited margin of safety. Livermore’s negative trend score and Veblen’s cultural critique pull the overall assessment down further, flagging a contrary price momentum and a growth narrative that may be pursued for its own sake. Together, these divergent scores illustrate how differing methodological lenses—liquidity, growth, cycle timing, valuation safety, market efficiency, trend following, and sociocultural factors—can lead to both converging and opposing conclusions about the same stock.
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟢 94
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 91
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 81
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟢 75
Exceptional company quality by Fisher's standards
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟢 73
Looks like a real 'buy and hold for a decade' candidate
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟢 65
The kind of quiet compounder a patient holder could actually stick with
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 63
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 61
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 60
Mixed — doesn't clearly pass Graham's tests
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 56
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 54
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 54
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 44
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 40
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 30
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Based on the last 287 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (1 bullish · 8 bearish · 2 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
High confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
-72.8%
Net Margin
-52.0%
EBITDA Margin
—
ROE
-11.1%
ROA
-10.3%
ROIC
—
EPS
-$1.28
Cash
$112.83M
Total Debt
—
Current Ratio
11.34
Debt/Equity
0.00
How is Fair Value calculated? →
Current Price
$36.69
Estimated Fair Value (DCF)
-$21.18
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-157.7%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
25.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 25.0% | $-91.83M | $-84.25M |
| 2 | 19.4% | $-109.63M | $-92.27M |
| 3 | 13.8% | $-124.70M | $-96.29M |
| 4 | 8.1% | $-134.83M | $-95.52M |
| 5 | 2.5% | $-138.20M | $-89.82M |
Base FCF (last actual year)
$-73.47M
Terminal Value
$-2.18B
Present Value of Terminal Value
$-1.42B
Enterprise Value
$-1.87B
Net Debt
$0
Equity Value
$-1.87B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$11.65
Tangible Book Value per Share (Tangible NAV)
$7.25
Sentiment based on basic keywords (not AI) — 5 positive, 13 neutral, 2 negative out of the last 20 articles.
Yahoo · 25.9.2026
Yahoo · 25.9.2026
SeekingAlpha · 14.9.2026
SeekingAlpha · 10.9.2026
MT Newswires · 9.9.2026
PR Newswire · 9.9.2026
Yahoo · 9.9.2026
Benzinga · 9.9.2026
Benzinga · 9.9.2026
Yahoo · 1.9.2026
PR Newswire · 1.9.2026
Benzinga · 1.9.2026
Benzinga · 1.9.2026
MT Newswires · 31.8.2026
MT Newswires · 31.8.2026
Yahoo · 31.8.2026
PR Newswire · 31.8.2026
Benzinga · 31.8.2026
PR Newswire · 28.8.2026
SeekingAlpha · 25.8.2026
IDEAYA Biosciences, Inc. (IDYA) currently has a StockIQ AI score of 47/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
IDYA currently scores 47/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, IDYA's estimated fair value is -$21.18, which is 157.7% below the current price of $36.69. This is one valuation model among several signals in the fair-value category, not a price target.
IDYA's technical score is 26/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Revenue growth (last year): 3024.4%; Earnings per share (EPS) growth: 61.9%; Free cash flow growth: 70.8%.
Based on the real signals StockIQ computed: Estimated fair value: -$21.18 vs. price $36.69 (-157.7%); Operating margin: -72.8% (negative); Net margin: -52.0% (negative).
StockIQ has no recorded dividend payment history for IDYA.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 2 purchases and 2 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Ruiz Briseno Andres | Open Market Sale | 7.7.2026 | 9,550 | -9,550 | $40.01 |
| Ruiz Briseno Andres | Exercise of Derivative Securities | 7.7.2026 | 9,550 | -9,550 | — |
| Ruiz Briseno Andres | Exercise of Derivative Securities | 7.7.2026 | 9,550 | +9,550 | $12.86 |
| Ruiz Briseno Andres | Exercise of Derivative Securities | 7.7.2026 | 36,016 | +9,550 | $12.86 |
| Ruiz Briseno Andres | Open Market Sale | 7.7.2026 | 26,466 | -9,550 | $40.01 |
| Ruiz Briseno Andres | Exercise of Derivative Securities | 7.7.2026 | 19,200 | -9,550 | — |
| Hampton Malcolm Garret | Grant/Award from Employer | 16.6.2026 | 20,000 | +20,000 | — |
| Morrison Scott W | Grant/Award from Employer | 16.6.2026 | 20,000 | +20,000 | — |
| MACKEY CATHERINE J | Grant/Award from Employer | 16.6.2026 | 20,000 | +20,000 | — |
| Stein Jeffrey | Grant/Award from Employer | 16.6.2026 | 20,000 | +20,000 | — |
| ROSEN TERRY J | Grant/Award from Employer | 16.6.2026 | 20,000 | +20,000 | — |
| YARNO WENDY L | Grant/Award from Employer | 16.6.2026 | 20,000 | +20,000 | — |
| YARNO WENDY L | Grant/Award from Employer | 16.6.2026 | 20,000 | +20,000 | — |
| ROSEN TERRY J | Grant/Award from Employer | 16.6.2026 | 20,000 | +20,000 | — |
| Stein Jeffrey | Grant/Award from Employer | 16.6.2026 | 20,000 | +20,000 | — |
| MACKEY CATHERINE J | Grant/Award from Employer | 16.6.2026 | 20,000 | +20,000 | — |
| Stein Jeffrey | Open Market Purchase | 2.3.2026 | 50,000 | +50,000 | $32.96 |
| Stein Jeffrey | Open Market Purchase | 2.3.2026 | 54,281 | +50,000 | $32.96 |
| Hata Yujiro S | Grant/Award from Employer | 30.1.2026 | 600,000 | +600,000 | — |
| Bleharski Joshua | Grant/Award from Employer | 30.1.2026 | 170,000 | +170,000 | — |
| Ruiz Briseno Andres | Grant/Award from Employer | 30.1.2026 | 80,000 | +80,000 | — |
| Beaupre Darrin | Grant/Award from Employer | 30.1.2026 | 175,000 | +175,000 | — |
| WHITE MICHAEL ANTHONY | Grant/Award from Employer | 30.1.2026 | 190,000 | +190,000 | — |
| DORMAN STUART | Grant/Award from Employer | 30.1.2026 | 155,000 | +155,000 | — |
| Snyder Douglas B. | Grant/Award from Employer | 30.1.2026 | 130,000 | +130,000 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
9,931,622 shares short as of 2026-09-15 · vs. 10,103,757 on 2026-08-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
63.1% of trading volume this week was short selling, vs. 74.8% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology